Abstract: Present invention relates to a formulation from natural product. The formulation is LDV liposomal formulation of Photo System-I (PSI) which causes apoptotic death of cancer cells through ROS generation and a simple way for targeted delivery of the said formulation specifically to melanoma cancer cell. LDV liposomal formulation of PSI was prepared for targeted delivery to melanoma cancer cell. Through this targeted delivery inventors have shown that LDV liposomal formulation of PSI specifically kills melanoma cancer cells leaving normal cells unaffected. The present invention elucidates that LDV liposomal formulation of PSI is more potent anti-cancer agent than doxorubicin for melanoma.

Abstract: The present investigation involves designing of a novel hexapeptide, which spontaneously self-assembles to form nanovesicles in physiological conditions. This peptide not only strongly binds with ?-tubulin near taxol binding site, but also binds with microtubule lattice in-vitro, as well as intracellular microtubule networks. Interestingly, it inhibits amyloid fibril formation upon co-incubation with A? peptide in-vitro and shows excellent neuroprotection against A? infected neuronal cell (PC12). Present invention provides a novel approach to produce a peptide-based therapeutics for neurodegenerative disease.

Abstract: The present investigation involves designing of a novel hexapeptide, which spontaneously self-assembles to form nanovesicles in physiological conditions. This peptide not only strongly binds with ?-tubulin near taxol binding site, but also binds with microtubule lattice in-vitro, as well as intracellular microtubule networks. Interestingly, it inhibits amyloid fibril formation upon co-incubation with A? peptide in-vitro and shows excellent neuroprotection against A? infected neuronal cell (PC12). Present invention provides a novel approach to produce a peptide-based therapeutics for neurodegenerative disease.